Aluminum Content of Parenteral Nutrition in Neonates: Measured Versus Calculated Levels
- 1 February 2010
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 50 (2) , 208-211
- https://doi.org/10.1097/mpg.0b013e3181aed70b
Abstract
Aluminum (Al) is associated with significant central nervous system toxicity and bone and liver damage. Because Al is a contaminant of parenteral nutrition (PN) components including calcium and phosphate additives, premature infants are at potentially high risk for toxicity. The US Food and Drug Administration (FDA) has mandated PN component product labeling and recommended maximum Al daily exposure limits. The objective of this article is to determine the actual Al content of neonatal PN solutions, compare these values to the calculated amounts from manufacturers' PN product labels, and ascertain whether the actual Al exposure exceeds the FDA recommended maximum of 5 μg · kg−1 · day−1. Samples from 40 neonatal patient PN solutions were selected for sampling and Al content determination. Samples were also taken from 16 manufacturer's component products used in PN formulation. All of the samples were sent to Mayo Laboratories for Al content measurement. The calculated Al concentrations in PN samples were determined from the manufacturer's labeled content. Both measured and calculated Al concentrations exceeded the FDA recommended safe limit of <5 μg · kg−1 · day−1. The actual measured Al content was significantly lower than the calculated Al content in both the patient PN solutions and the component product samples. Al exposure exceeded the FDA recommended maximum limit for all patient samples; however, the actual measured Al content of all the samples was significantly less than the calculated Al content based on manufacturer's labels. These findings suggest that manufacturers label their products with actual Al content at the time of product release rather than at time of expiration. Periodic monitoring of Al levels should be considered with prolonged PN therapy. Changes in manufacturing processes, including the use of better raw materials, are essential to reduce Al contamination to meet FDA mandates.Keywords
This publication has 19 references indexed in Scilit:
- Aluminum Exposure From Pediatric Parenteral Nutrition: Meeting the New FDA RegulationJournal of Parenteral and Enteral Nutrition, 2008
- Measured versus estimated aluminum content of parenteral nutrient solutionsAmerican Journal of Health-System Pharmacy, 2007
- Effect of addiivet selection on calculated aluminum content of parenteral nutrient solutionsAmerican Journal of Health-System Pharmacy, 2007
- Recent developments in aluminium contamination of products used in parenteral nutritionCurrent Opinion in Clinical Nutrition and Metabolic Care, 2006
- A.S.P.E.N. Statement on Aluminum in Parenteral Nutrition SolutionsNutrition in Clinical Practice, 2004
- Contribution of the raw material to the aluminum contamination in parenteralsJournal of Parenteral and Enteral Nutrition, 2002
- Influence of the glass packing on the contamination of pharmaceutical products by aluminium. Part II: Amino acids for parenteral nutritionJournal of Trace Elements in Medicine and Biology, 2001
- Aluminum Neurotoxicity in Preterm Infants Receiving Intravenous-Feeding SolutionsNew England Journal of Medicine, 1997
- Aluminium loading in children receiving long-term parenteral nutritionClinical Nutrition, 1990
- Nutritional Aspects of Aluminium ToxicityNutrition Research Reviews, 1990